TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02698007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Description: Fiberoptic bronchoscopy with the use of LMA
Study: NCT02805439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 15mg
Description: One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 50mg
Description: One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
Study: NCT01145170

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
Study: NCT01234844

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: care of guinea pigs
Description: twice weekly sessions of care with guinea pigs

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: guinea pigs
Description: twice weekly pet therapy and twice weekly usual  occupational therapy
Study: NCT02129582

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: Undergo TMI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myeloid progenitor cell transplantation
Description: Undergo allogeneic hematopoietic progenitor cell transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00880048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orvepitant
Description: neurokinin-1 antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orvepitant
Description: neurokinin-1 antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match orvepitant 30 mg and 60 mg
Study: NCT03471611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ Cells
Description: The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Description: 5mg/kg twice daily
Study: NCT02768571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day \* 21 days with rehabilitation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- saline 100 ml/day \* 21 days with rehabilitation
Study: NCT05480358

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fasting-Mimicking Diet ProlonADTM
Description: Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet ProlonADTM
Description: Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
Study: NCT00427752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transgastric endoscopic peritoneoscopy.
Description: Exploration of the abdominal area
Study: NCT01932450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic denervation
Description: One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antihypertensive drugs
Description: antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
Study: NCT04377594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio frequency ablation
Description: Two different radio frequency ablation procedures
Study: NCT04641312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3457263
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3457263
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study: NCT04311151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: own seizures visualization
Description: At the hospital discharge, patients
Study: NCT03128736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole group
Description: Esomeprazole 40mg qd
Study: NCT04641312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00783211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine, 5 mg oral tablets, once daily for 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fexofenadine
Description: fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, once daily for 15 days
Study: NCT03146052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl
Description: PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl
Description: PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
Study: NCT01932450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihypertensive drugs
Description: antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
Study: NCT04258059

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active household UV water treatment device
Description: This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive household UV water treatment device
Description: This sham device will use a lamp not emitting germicidal UV.
Study: NCT01870024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: clonazepam 0,015 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: clonazepam 0,015 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin
Description: fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo 20 mg/kg by intravenous infusion over a period of 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
Study: NCT03128736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole group
Description: Dexlansoprazole 60mg qd
Study: NCT04286919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students
Description: A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students
Description: A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
Study: NCT03027921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastography
Study: NCT03329976

Intervention type: OTHER
Intervention: measurement of visual acuity
Description: complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
Study: NCT01201759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days
Description: Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days
Description: Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
Study: NCT01870024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
Study: NCT00923234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
Study: NCT04496791

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)
Description: HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)
Description: HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
Study: NCT05099146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pictures
Description: pictures with brushing technique demonstrated technique for proper brushing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: video of brushing technique demonstrated technique for proper brushing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control
Description: oral hygiene instructions provided
Study: NCT02817152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal ultrasonic debridement
Description: Periodontal pockets received periodontal ultrasonic debridement intervention.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periodontal ultrasonic debridement
Description: Periodontal pockets received periodontal ultrasonic debridement intervention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement plus low-level laser therapy
Description: Ultrasonic debridement plus low-level laser therapy.
Study: NCT04021394

Intervention type: DIAGNOSTIC_TEST
Intervention: CellSearch CTC platform
Description: epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs

Intervention type: DIAGNOSTIC_TEST
Intervention: CellSearch CTC platform
Description: epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs

Intervention type: DIAGNOSTIC_TEST
Intervention: CellSearch CTC platform
Description: epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs

Intervention type: DIAGNOSTIC_TEST
Intervention: CellSearch CTC platform
Description: epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs

Intervention type: DIAGNOSTIC_TEST
Intervention: Parsortix CTC platform
Description: EMT-independent platform

Intervention type: DIAGNOSTIC_TEST
Intervention: Parsortix CTC platform
Description: EMT-independent platform
Study: NCT01637662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides
Description: I.V. infusion between 0.2-3 microgram over 20 minutes
Study: NCT01230840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: wheat dextrin
Description: 5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
Study: NCT04610008

Intervention type: OTHER
Intervention: No intervention. Purely observation
Description: Retrospective image analysis of the shape of the optic nerve head in both groups

Intervention type: OTHER
Intervention: No intervention. Purely observation
Description: Retrospective image analysis of the shape of the optic nerve head in both groups
Study: NCT01201759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
Description: Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
Description: Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
Study: NCT04177017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no.
Study: NCT03684265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Capsule (Test)
Description: single dose
Study: NCT04021394

Intervention type: DIAGNOSTIC_TEST
Intervention: Parsortix CTC platform
Description: EMT-independent platform

Intervention type: DIAGNOSTIC_TEST
Intervention: Parsortix CTC platform
Description: EMT-independent platform
Study: NCT03513965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptoms as Positive Signals Mindset
Description: In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptoms as Side Effects Mindset
Description: In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
Study: NCT04108585

Intervention type: PROCEDURE
Intervention: HFO therapy
Description: HFO therapy from mechanical ventilation

Intervention type: PROCEDURE
Intervention: CPAP therapy
Description: CPAP therapy from mechanical ventilation
Study: NCT01980706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen is a GABA-B agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen is a GABA-B agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill containing no pharmacologically active substance.
Study: NCT02237157

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, local delivery
Description: Intra-arterial targeted drug delivery

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, local delivery
Description: Intra-arterial targeted drug delivery

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, local delivery
Description: Intra-arterial targeted drug delivery

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine, local delivery
Description: Intra-arterial targeted drug delivery
Study: NCT04419246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia will be applied in accordance with standard procedures

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia will be applied in accordance with standard procedures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: general anesthesia will be applied in accordance with standard procedures
Study: NCT04507763

Intervention type: DRUG
Intervention: Etanercept
Description: Patients with ankylosing spondylitis as provided in real world practice
Study: NCT00501215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parathyroid Surgery
Description: Parathyroid surgery 1-3 weeks after the first PSG.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Interview
Description: Interview about sleep quality lasting 15-20 minutes.
Study: NCT04120870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate Injection 0.2 mg/kg
Description: The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
Study: NCT02177006

Intervention type: BEHAVIORAL
Intervention: Sun Protection Program
Description: The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys
Study: NCT02903238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Lactose capsule
Study: NCT04120870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine injection 2 mg/kg
Description: The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
Study: NCT03243084

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: XCSITE100 Stimulator Sham
Description: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
Study: NCT00501215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Interview
Description: Interview about sleep quality lasting 15-20 minutes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Parathyroid Surgery
Description: Parathyroid surgery after completing the second PSG and after the study participation ends.